Article Data

  • Views 381
  • Dowloads 115

Original Research

Open Access

Sequencing of SMAD4 somatic variation in patients with serous ovarian cancer

  • AP. Chen1,*,
  • HF. Zhao2
  • ZX.Ding1
  • YY. Qi3
  • C. Wang1
  • JL. Wang4

1Gynecology, The Affiliated Hospital of Qingdao University, Qingdao (China)

DOI: 10.31083/j.ejgo.2020.01.4643 Vol.41,Issue 1,February 2020 pp.85-88

Published: 15 February 2020

*Corresponding Author(s): AP. Chen E-mail:


Objective: A previous study has indicated SMAD4 mutations identified in patients with serous ovarian cancer. The aim of study is to analyze the SMAD4 mutation in Chinese people with primary serous ovarian cancer and attempt to build the correlation between the genotype and clinical phenotype or parameters of clinical pathological; t. Materials and Methods: The authors collected 90 serous ovarian cancer cases with primary samples that were identified by pathologist. DNA was extracted from paraffin-embedded tumor tissues. The exon 2, 8, 9 and 11 of SMAD4 muta-tion hotspots were screened by Sanger sequencing. Results: The authors detected neither heterozygous mutations nor homozygous mu-tations in exon 2, 8, 9, and 11 of SMAD4 in 90 cases of serous ovarian cancer. However, they identified a single nucleotide polymorphism (SNP) (rs77389132) in the intron 2 regions and searched the ExAC website ( for the SNP at Chr18: 48573689 and allele is A/G. Conclusions: The mutational rate of exons 2, 8, 9, and 11 of SMAD4 in serous ovarian cancer may be rare in Chinese people with primary serous ovarian cancer. Therefore, Seeking SMAD4 mutation for ovarian cancer susceptible population and individual treatment still need further pursuing.


Serous ovarian cancer; SMAD4; Somatic variation; Clinico-pathological parameters.

Cite and Share

AP. Chen,HF. Zhao,ZX.Ding,YY. Qi,C. Wang,JL. Wang. Sequencing of SMAD4 somatic variation in patients with serous ovarian cancer. European Journal of Gynaecological Oncology. 2020. 41(1);85-88.


[1] Malpica A., Deavers M.T., Lu K., Bodurka D.C., Atkinson E.N., Gershenson D.M., et al.: “Grading ovarian serous carcinoma using a two-tier system”. Am. J. Surg. Pathol., 2004, 28, 496.

[2] Schwarz R.F., Ng C.K., Cooke S.L., Newman S., Temple J., Piskorz A.M., et al.: “Spatial and temporal heterogeneity in high-grade serous ovarian cancer: a phylogenetic analysis”. PLoS Med., 2015, 12, e1001789.

[3] Kou T., Kanai M., Yamamoto Y., Kamada M., Nakatsui M., Sakuma T., et al.: “Clinical sequencing using a next-generation sequencingbased multiplex gene assay in patients with advanced solid tumors”. Cancer Sci., 2017, 108, 144.

[4] Rogozin I.B., Pavlov Y.I., Goncearenco A., De S., Lada A.G., Poliakov E., et al.: “Mutational signatures and mutable motifs in cancer genomes”. Brief. Bioinform., 2018, 19, 1085.

[5] Ross S., Hill C.S.: “How the Smads regulate transcription”. Int. J. Biochem. Cell. Biol., 2008, 40, 383.

[6] Li Q.: “Inhibitory SMADs: potential regulators of ovarian function”. Biol. Reprod., 2015, 92, 50.

[7] Thiagalingam S., Lengauer C., Leach F.S., Schutte M., Hahn S.A., Overhauser J., et al.: “Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers”. Nat. Genet., 1996, 13, 343.

[8] Yang G., Yang X.: “Smad4-mediated TGF-beta signaling in tumorigenesis”. Int. J. Biol. Sci., 2010, 6, 1.

[9] Padua D., Massague J.: “Roles of TGF beta in metastasis”. Cell Res., 2009, 19, 89.

[10] Singh P., Srinivasan R., Wig J.D.: “SMAD4 genetic alterations predict a worse prognosis in patients with pancreatic ductal adenocarcinoma”. Pancreas, 2012, 41, 541.

[11] Tone A.A., McConechy M.K., Yang W., Ding J., Yip S., Kong E., et al.: “Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomas”. BMC Cancer, 2014, 14, 982.

[12] Schutte M., Hruban R.H., Hedrick L., Cho K.R., Nadasdy G.M., Weinstein C.L., et al.: “DPC4 gene in various tumor types”. Cancer Res., 1996, 56, 2527.

[13] O'Brien C.: “New tumor suppressor found in pancreatic cancer”. Science, 1996, 271, 294.

[14] Wu Y., Yu X., Yi X., Wu K., Dwabe S., Atefi M., et al.: “Aberrant Phosphorylation of SMAD4 Thr277-Mediated USP9x-SMAD4 Interaction by Free Fatty Acids Promotes Breast Cancer Metastasis”. Cancer Res., 2017, 77, 1383.

[15] Haeger S.M., Thompson J.J., Kalra S., Cleaver T.G., Merrick D., Wang X.J., et al.: “Smad4 loss promotes lung cancer formation but increases sensitivity to DNA topoisomerase inhibitors”. Oncogene, 2016, 35, 577.

[16] Jansen M.P., Martens J.W., Helmijr J.C., Beaufort C.M., van Marion R., Krol NM., et al.: “Cell-free DNA mutations as biomarkers in breast cancer patients receiving tamoxifen”. Oncotarget, 2016, 7, 43412.

[17] Zavesky L., Jancarkova N., Kohoutova M.: “Ovarian cancer: origin and factors involved in carcinogenesis with potential use in diagnosis, treatment and prognosis of the disease”. Neoplasma, 2011, 58, 457.

[18] David C.J., Huang Y.H., Chen M., Su J., Zou Y., Bardeesy N., et al.: “TGF-beta Tumor Suppression through a Lethal EMT”. Cell, 2016, 164, 1015.

[19] Antony M.L., Nair R., Sebastian P., Karunagaran D.: “Changes in expression, and/or mutations in TGF-beta receptors (TGF-beta RI and TGF-beta RII) and Smad 4 in human ovarian tumors”. J. Cancer Res. Clin. Oncol., 2010, 136, 351.

[20] Kennedy B.A., Deatherage D.E., Gu F., Tang B.H., Michael Chan W.Y., Nephew K.P., et al.: “ChIP-seq defined genome-wide map of TGFbeta/SMAD4 targets: implications with clinical outcome of ovarian cancer”. PloS One, 2011, 6, e22606.

[21] Lassus H., Salovaara R., Aaltonen L.A., Butzow R.: “Allelic analysis of serous ovarian carcinoma reveals two putative tumor suppressor loci at 18q22-q23 distal to SMAD4, SMAD2, and DCC”. Am. J. Pathol., 2001, 159, 35.

[22] Wosiak A., Wodzinski D., Kolasa M., Sałagacka-Kubiak A., Balcerczak E.: “SMAD-4 gene expression in human colorectal cancer: Comparison with some clinical and pathological parameters”. Pathol. Res. Pract., 2017, 213, 45.

[23] Campos F.G., Figueiredo M.N., Martinez C.A.: “Colorectal cancer risk in hamartomatous polyposis syndromes”. World J. Gastrointest. Surg., 2015, 7, 25.

[24] Patch A.M., Christie E.L., Etemadmoghadam D., Garsed D.W., George J., Fereday S., et al.: “Whole-genome characterization of chemoresistant ovarian cancer”. Nature, 2015, 521, 489.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time